Back to Search
PATRICK VOORHEES, M.D.
M.D.
Anatomic Pathology & Clinical Pathology Physician
NPI: 1609007152IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anatomic Pathology & Clinical Pathology PhysicianPrimary
Pathology — Anatomic Pathology & Clinical Pathology
Code: 207ZP0102X
01064138A(IN)
Education
UNIFORMED SERVICES UHS FE HEBERT SCHOOL OF MED
Class of 2005
Research & Publications (20)
A case of hook effect in the serum free light chain assay using the Olympus AU400e.
PMID 18996106·Clin Biochem·2009
5-case
Direct growth of compound semiconductor nanowires by on-film formation of nanowires: bismuth telluride.
PMID 19588906·Nano Lett·2009
8-other
Three-dimensional analysis of solid oxide fuel cell Ni-YSZ anode interconnectivity.
PMID 19144260·Microsc Microanal·2009
8-other
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
PMID 19344406·Br J Haematol·2009
4-observational
Direct measurement of dopant distribution in an individual vapour-liquid-solid nanowire.
PMID 19421218·Nat Nanotechnol·2009
8-other
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
PMID 18668698·Hematol Oncol·2009
3-trial
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
PMID 19050304·Blood·2009
8-other
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
PMID 18305219·Blood·2008
8-other
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
PMID 18765533·Clin Cancer Res·2008
8-other
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
PMID 17146676·Ann Hematol·2007
3-trial
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
PMID 17975159·Clin Cancer Res·2007
8-other
Malignant insulinoma: a rare presentation of a rare tumor.
PMID 17719587·Gastrointest Endosc·2007
5-case
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
PMID 17591945·Blood·2007
4-observational
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
PMID 17562254·Clin Lymphoma Myeloma·2007
6-review
Coarsening of bicontinuous structures via nonconserved and conserved dynamics.
PMID 17358326·Phys Rev E Stat Nonlin Soft Matter Phys·2007
8-other
The proteasome and proteasome inhibitors in cancer therapy.
PMID 16402903·Annu Rev Pharmacol Toxicol·2006
6-review
Orientation dependence of strained-Ge surface energies near (001): role of dimer-vacancy lines and their interactions with steps.
PMID 16605929·Phys Rev Lett·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 8901 ROCKVILLE PIKE
BETHESDA, MD 20889 - Phone
- (301) 295-4455
Quick Facts
- NPI
- 1609007152
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 21
- Publications
- 20
Are you this provider?
Claim Your Profile